Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John C Breneman

Showing results (31-40 of 47) with videos related to

Pageof 5
Sort By:
Pediatric Blood & Cancer|February 8, 2011
Local control and outcome in children with localized vaginal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma committee of the Children's Oncology GroupDavid O Walterhouse, Jane L Meza, John C Breneman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 2, 2011
Results of the Intergroup Rhabdomyosarcoma Study Group D9602 protocol, using vincristine and dactinomycin with or without cyclophosphamide and radiation therapy, for newly diagnosed patients with low-risk embryonal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology GroupR Beverly Raney, David O Walterhouse, Jane L Meza, et al.
Cancer|February 18, 2017
Reduction of cyclophosphamide dose for patients with subset 2 low-risk rhabdomyosarcoma is associated with an increased risk of recurrence: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology GroupDavid O Walterhouse, Alberto S Pappo, Jane L Meza, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 2014
Shorter-duration therapy using vincristine, dactinomycin, and lower-dose cyclophosphamide with or without radiotherapy for patients with newly diagnosed low-risk rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology GroupDavid O Walterhouse, Alberto S Pappo, Jane L Meza, et al.
International Journal of Radiation Oncology, Biology, Physics|June 14, 2002
A multi-institutional review of radiosurgery alone vs. radiosurgery with whole brain radiotherapy as the initial management of brain metastasesPenny K Sneed, John H Suh, Steven J Goetsch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 23, 2009
Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: children's oncology group study D9803Carola A S Arndt, Julie A Stoner, Douglas S Hawkins, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2002
Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma--a report from the Intergroup Rhabdomyosarcoma Study IVJohn C Breneman, Elizabeth Lyden, Alberto S Pappo, et al.
JAMA Oncology|October 23, 2022
Proton FLASH Radiotherapy for the Treatment of Symptomatic Bone Metastases: The FAST-01 Nonrandomized TrialAnthony E Mascia, Emily C Daugherty, Yongbin Zhang, et al.
Medical and Pediatric Oncology|February 9, 2002
Treatment of children and adolescents with localized parameningeal sarcoma: experience of the Intergroup Rhabdomyosarcoma Study Group protocols IRS-II through -IV, 1978-1997Richard Beverly Raney, Jane Meza, James R Anderson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 24, 2018
Demographic and Treatment Variables Influencing Outcome for Localized Paratesticular Rhabdomyosarcoma: Results From a Pooled Analysis of North American and European Cooperative GroupsDavid O Walterhouse, Donald A Barkauskas, David Hall, et al.
Pageof 5

Showing results (31-40 of 47) with videos related to

Sort By:
Pageof 5
Pediatric Blood & Cancer|February 8, 2011
Local control and outcome in children with localized vaginal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma committee of the Children's Oncology GroupDavid O Walterhouse, Jane L Meza, John C Breneman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 2, 2011
Results of the Intergroup Rhabdomyosarcoma Study Group D9602 protocol, using vincristine and dactinomycin with or without cyclophosphamide and radiation therapy, for newly diagnosed patients with low-risk embryonal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology GroupR Beverly Raney, David O Walterhouse, Jane L Meza, et al.
Cancer|February 18, 2017
Reduction of cyclophosphamide dose for patients with subset 2 low-risk rhabdomyosarcoma is associated with an increased risk of recurrence: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology GroupDavid O Walterhouse, Alberto S Pappo, Jane L Meza, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 2014
Shorter-duration therapy using vincristine, dactinomycin, and lower-dose cyclophosphamide with or without radiotherapy for patients with newly diagnosed low-risk rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology GroupDavid O Walterhouse, Alberto S Pappo, Jane L Meza, et al.
International Journal of Radiation Oncology, Biology, Physics|June 14, 2002
A multi-institutional review of radiosurgery alone vs. radiosurgery with whole brain radiotherapy as the initial management of brain metastasesPenny K Sneed, John H Suh, Steven J Goetsch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 23, 2009
Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: children's oncology group study D9803Carola A S Arndt, Julie A Stoner, Douglas S Hawkins, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2002
Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma--a report from the Intergroup Rhabdomyosarcoma Study IVJohn C Breneman, Elizabeth Lyden, Alberto S Pappo, et al.
JAMA Oncology|October 23, 2022
Proton FLASH Radiotherapy for the Treatment of Symptomatic Bone Metastases: The FAST-01 Nonrandomized TrialAnthony E Mascia, Emily C Daugherty, Yongbin Zhang, et al.
Medical and Pediatric Oncology|February 9, 2002
Treatment of children and adolescents with localized parameningeal sarcoma: experience of the Intergroup Rhabdomyosarcoma Study Group protocols IRS-II through -IV, 1978-1997Richard Beverly Raney, Jane Meza, James R Anderson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 24, 2018
Demographic and Treatment Variables Influencing Outcome for Localized Paratesticular Rhabdomyosarcoma: Results From a Pooled Analysis of North American and European Cooperative GroupsDavid O Walterhouse, Donald A Barkauskas, David Hall, et al.
Pageof 5